INTRODUCTION AND AIMS:
Anemia is a common comorbidity and is a major cause of morbidity and mortality among hemodialysis (HD) patients and erythropoiesis-stimulating agents (ESA) have been remarkably improving prognosis of HD patients with anemia. Nevertheless, factors related to required dose of ESA for target hemoglobin level in a certain period have been unclear. Red blood cell lifespan is reportedly related to required ESA dose with high correlation; however, measurement of red blood cell lifespan is generally difficult. Newly generated hemoglobin levels, reticulocyte hemoglobin levels, without ESA can be a key factor of ESA efficacy, because high basal level of reticulocyte generation seems quite favorable for anemia control. We aimed to investigate whether basal level of reticulocyte hemoglobin without ESA is related to required ESA dose in HD patients. METHODS: This study was conducted within the low-dose iron study. Data of one hundred and forty-six patients were used for this analysis as a single arm. Ferritin and transferrin saturation were measured at two-month intervals. Iron was administered for two months according to assignments of low (20mg) or standard (40 mg) intravenous elemental iron per week when HD patients showed iron deficiency (transferrin saturation < 20% and ferritin < 100ng/ml). Hemoglobin and reticulocyte hemoglobin were measured every week and every two month, respectively. Short acting ESA was administrated to obtain a target hemoglobin level of 10-11 g/dL. Basal levels of reticulocyte hemoglobin without ESA administerd in the previous one week were used as basal reticulocyte hemoglobin. RESULTS: Mean age and male proportion of the whole subjects were 68.9 6 11.8 years and 67%, respectively. Mean hemoglobin levels during the evaluation period of 6 months were 10.6 6 0.5 g/dL and ESA doses were 3876.9 6 2142.6 IU/week. Mean dose of iron administration per 6 months were 141.1 6 191.8mg. Average levels of basal reticulocyte hemoglobin were 98.1 6 56.8 mg/dL. Basal reticulocyte hemoglobin were closely correlated with required dose of erythropoiesis-stimulating agents (r¼0.642, p<0.001). Similarly, the analysis stratified by assignments of the low and standard iron supplementation showed the significant relations between basal reticulocyte hemoglobin levels and ESA dose. CONCLUSIONS: Basal level of reticulocyte hemoglobin is closely correlated with required dose of erythropoiesis-stimulating agents in hemodialysis patients with anemia. We study hemodialysis sessions of 534 patients in our 4 hemodialysis centers during June 2017. A total of 137 patients was excluded to our study due to different causes. Finally, we study 397 patients. NLI was calculated by the quotient between absolute value of neutrophils and absolute value of lymphocytes in the hemogram. The erythropoietin hyporresponsiveness index (EHRI) was obtained calculating the weekly dose of erythropoietin divided by the dry weight and divided again by the levels of serum hemoglobin. RESULTS: EHRI was divide into quartiles and compared with the NLI averages in the four groups, there was statistically significant differences (p¼0.00058) (Figure 1 ). In the regression analyzes, the NLI value was able to predict the EHRI (p>0.0001) (R 2 0.045) (Figure 2) . CONCLUSIONS: NLI could be considered an acceptable biomarker of erythropoietin resistance. Nephrology, Ain Shams Univesity, Cairo, Egypt INTRODUCTION AND AIMS: Erythropoietin (EPO) is an extensively glycosylated protein hormone. The development of neutralizing anti-EPO antibodies against recombinant form of EPO was found to be associated with pure red cell aplasia. These antibodies probably cross react with the patient's endogenous EPO and lead to anemia that can be more severe than even before the onset of EPO therapy.Aims To estimate the prevalence of anti-Epo antibody in prevalent HD patients and its association with anemia and factors causing resistance to EPO treatment. METHODS: We studied a cross sectional 90 ESRD patients were on recombinant human erythropoietin > 6 months and their hemoglobin < 11 g /dL. Excluding patients with malnourishment, Chronic Liver Disease, hypothyroidism, ongoing active autoimmune disease, active infection, on steroid therapy, with bleeding or hemolysis and elderly. Serum anti Epo antibody was measured for all Patients that were divided into 2 groups: anti Epo antibody positive and negative RESULTS: The prevalence of anti-EPO antibody was 45.6% (41 patients) . Anti-Epo antibody positive patients (N¼41) Showed lower hemoglobin level, serum iron and Transferrin saturation with mean 6SD values 8.6060. 99, 52.91616.30, 22.6268.27 respectively also lower MCHC and PTH with median (IQR) 29.7 (2.50), 276 ( 251.549) respectively. On comparing it with antibody negative patients (N¼49) there were significant statistical differences with p values (< 0.0001), (0.038), (0.034), (0.002), (0.037) respectively . These patients received higher iron doses, EPO doses with high EPO resistance index with median (IQR) values 100 (100) mg/week, 8000 (4000) IU/ week, 10.79 (8.495) respectively. On comparing it with antibody negative patients p values were (0.230), (0.006), (0.0001) respectively. 58.5% (24 patients) received Epo treatment by S.C route and it has a significant relation to anti-Epo antibody development compared to antibody negative group p value (0.001*) . There were significant 
